Theravance Biopharma Inc (TBPH) saw an uptrend of 7.61% in the recent trading with $9.61 being its most recent. The current price level -20.12% lower than the highest price of $12.03 marked by the stock while trading over the past 52-weeks, whereas it is 17.05% higher than the lowest price of $8.21 the company dropped to over past 52-weeks. The latest news story on TBPH appeared in (PR Newswire) under the title “Theravance Biopharma, Inc. to Host Virtual Key Opinion Leader (KOL) Event to Discuss Ampreloxetine’s Potential for the Treatment of Symptomatic Neurogenic Orthostatic Hypotension (nOH) in Patients with Multiple System Atrophy (MSA) on May 23, 2024”.
Squeezing the time span to 30 day period shows us the stock is currently trading -7.95% below one month high and is +13.06% above of the lowest during that time. Looking into the simple moving average, Theravance Biopharma Inc (TBPH)’s stock stands at a SMA-50 of $8.93 while that of 5-day is reading $9.41.
Daily rise and fall of price influence many of the traders, and in order to overcome the fluctuating effect of that and to watch the stock closely, traders focus more on stock’s 200-day moving average. At various points in trading activity, investors are more likely to be making use of that measure as a strong indicator in figuring out their support and resistance levels, and TBPH’s SMA-200 as of now is $9.66.
Do analysts rate it as a buy, sell or hold?
Irrespective of recent performance, what’s important is what the future holds. In uncertain economic times, a clear picture is difficult to get. Analysts generally have a good understanding of the market works, which gives them a leg up in making predictions. Analyst ratings are often compiled into a single score from 1 to 5. The score of 1 signifies buy or strong buy, the score of 2 signifies outperform, the score of 3 means hold, and the score of 4 indicates underperform. The simple numeric range of brokerage firm referenced at the scale of 1 to 5 reads a current average recommendation of 1.80 for the stock.
Theravance Biopharma Inc Earnings – What Happened With TBPH
Coming around sales and income figures on TBPH Stock Income Statement, public trading companies under normal circumstances post earnings and revenues near to average estimates by the Wall Street analysts, but those could came either above or below estimates and known as surprise factor. Theravance Biopharma Inc (TBPH) last released financial results for the quarter that ended 12/30/2023, posting a surprise factor of -13.30% for net revenue.
TBPH – Theravance Biopharma Inc Stock Earnings Estimates
The perspective of Theravance Biopharma Inc (NASDAQ:TBPH)’s current quarter earnings identifies that analysts are in consensus over the estimate of -0.15 for stock’s EPS in the current quarter. 3 analysts covering the stock at Wall Street were agreed upon that EPS consensus. Company’s EPS for the last quarter was -0.17.
Investors get the exact data about the key information of institutional ownership in a listed company through its 13F filings at the Stock Exchange Commission (SEC). The total number of common shares currently owned by the public is 48.09 million. TBPH does have institutional investors; and they hold 101.66% of the stock.
Theravance Biopharma Inc – Insider Activity and Holdings
As on Dec 30, 2023, Weiss Asset Management Lp was the top most holder in Theravance Biopharma Inc (NASDAQ:TBPH) with an ownership of 7.46 million shares of the company or 15.36% of the stake worth $71.66 million. The filing also reveals Baupost Group, Inc,.(The) LLC as the second largest holder in the company with a control over 15.28% of the outstanding shares. Its stake is worth $71.3 million for having 7.42 million shares in hand.
Madison Avenue Partners, LP also came holding a key position in the company during the recent quarter and it now holds 14.44% of the outstanding shares. With this there are now 170 institutions which have possession in TBPH’s shares.
Analyst ratings are often compiled into a single score from 1 to 5. The score of 1 signifies buy or strong buy, the score of 2 signifies outperform, the score of 3 means hold, and the score of 4 indicates underperform. The simple numeric range of brokerage firm referenced at the scale of 1 to 5 reads a current average recommendation of 1.80 for the stock.
The liquidity is a key characteristic of any stock and is the main point of focus of both short-term as well as long term investors before start trading into a stock. In recently reported quarter, Theravance Biopharma Inc has a debt to equity ratio of 0.23.
Technical Analysis of Theravance Biopharma Inc (NASDAQ:TBPH) stock
To comprehend better with the trade moves and investors’ behavior, exploring the short, medium and long term technical indicators along with average volume of a stock is an effective way to make use of. When looking into those indicators for Theravance Biopharma Inc (TBPH), we notice that the stock’s 20-day average volume is at 445,580 shares. Medium term indicators at an average of 50% are spotting the stock at Sell with its 50-day average volume of 378,272 shares. And to end with, TBPH’s 100-day average volume are 390,690 shares.
